Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
- New analysis of age-related macular degeneration (AMD) progression in Phase 2 FILLY study accepted as late-breaking oral presentation at European Society of Retina Specialists Congress (EURETINA)
- Pegcetacoplan targets C3, and has the potential to control the irreversible lesion growth in GA, an advanced form of AMD and leading cause of blindness
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that a post hoc analysis of the Phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETINA 2020 Virtual.
This new analysis of the FILLY study demonstrates that pegcetacoplan impacts the progression of nascent GA,1,2 the earlier stage of disease that precedes atrophy, in areas of the retina outside of GA lesions. The data are from a collaboration with the Doheny Image Reading Research Lab, and will be presented by SriniVas Sadda, M.D. at the “Late Breaking & Reviews” oral session.
“We are excited that this post hoc analysis of the FILLY study was selected by EURETINA as a late-breaking presentation. These new data highlight the potential of targeting C3 with pegcetacoplan to transform the treatment of GA, a disease that leads to irreversible vision loss and has no approved treatments,” said Federico Grossi, M.D., Ph.D., Chief Medical Officer of Apellis.
About Pegcetacoplan (APL-2)
Pegcetacoplan is an investigational, targeted C3 therapy designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Apellis is evaluating pegcetacoplan in several clinical studies including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), and C3 glomerulopathy (C3G). Pegcetacoplan was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of PNH and the treatment of GA. For additional information regarding our clinical trials, visit https://apellis.com/our-science/clinical-trials.